Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.83
TROV's Cash to Debt is ranked higher than
61% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. TROV: 1.83 )
TROV' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 1.83

Equity to Asset 0.29
TROV's Equity to Asset is ranked higher than
56% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. TROV: 0.29 )
TROV' s 10-Year Equity to Asset Range
Min: -9.76   Max: 0.75
Current: 0.29

-9.76
0.75
F-Score: 2
Z-Score: 0.42
M-Score: -5.24
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -5337.86
TROV's Operating margin (%) is ranked higher than
53% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. TROV: -5337.86 )
TROV' s 10-Year Operating margin (%) Range
Min: -5337.5   Max: -1077.56
Current: -5337.86

-5337.5
-1077.56
Net-margin (%) -5116.07
TROV's Net-margin (%) is ranked higher than
53% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. TROV: -5116.07 )
TROV' s 10-Year Net-margin (%) Range
Min: -5116.07   Max: -867.83
Current: -5116.07

-5116.07
-867.83
ROE (%) -94.02
TROV's ROE (%) is ranked higher than
59% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. TROV: -94.02 )
TROV' s 10-Year ROE (%) Range
Min: -104.7   Max: -99.68
Current: -94.02

-104.7
-99.68
ROA (%) -47.92
TROV's ROA (%) is ranked higher than
65% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. TROV: -47.92 )
TROV' s 10-Year ROA (%) Range
Min: -288.72   Max: -51.11
Current: -47.92

-288.72
-51.11
ROC (Joel Greenblatt) (%) -1818.69
TROV's ROC (Joel Greenblatt) (%) is ranked higher than
65% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. TROV: -1818.69 )
TROV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -25886.96   Max: -1878.69
Current: -1818.69

-25886.96
-1878.69
» TROV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with TROV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 15.91
TROV's P/B is ranked higher than
51% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. TROV: 15.91 )
TROV' s 10-Year P/B Range
Min: 3.26   Max: 69.3
Current: 15.91

3.26
69.3
P/S 700.00
TROV's P/S is ranked higher than
51% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. TROV: 700.00 )
TROV' s 10-Year P/S Range
Min: 80   Max: 704
Current: 700

80
704
EV-to-EBIT -10.49
TROV's EV-to-EBIT is ranked lower than
51% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TROV: -10.49 )
TROV' s 10-Year EV-to-EBIT Range
Min: -27.2   Max: -3
Current: -10.49

-27.2
-3
Current Ratio 6.18
TROV's Current Ratio is ranked higher than
79% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. TROV: 6.18 )
TROV' s 10-Year Current Ratio Range
Min: 0.08   Max: 15.13
Current: 6.18

0.08
15.13
Quick Ratio 6.18
TROV's Quick Ratio is ranked higher than
80% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. TROV: 6.18 )
TROV' s 10-Year Quick Ratio Range
Min: 0.08   Max: 15.13
Current: 6.18

0.08
15.13
Days Sales Outstanding 74.30
TROV's Days Sales Outstanding is ranked higher than
80% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 111.38 vs. TROV: 74.30 )
TROV' s 10-Year Days Sales Outstanding Range
Min: 74.3   Max: 140.06
Current: 74.3

74.3
140.06

Valuation & Return

vs
industry
vs
history
Price/Net Cash 19.44
TROV's Price/Net Cash is ranked higher than
70% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 87.00 vs. TROV: 19.44 )
TROV' s 10-Year Price/Net Cash Range
Min: 5.68   Max: 77
Current: 19.44

5.68
77
Price/Net Current Asset Value 18.43
TROV's Price/Net Current Asset Value is ranked higher than
67% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 28.08 vs. TROV: 18.43 )
TROV' s 10-Year Price/Net Current Asset Value Range
Min: 5.63   Max: 69.3
Current: 18.43

5.63
69.3
Price/Tangible Book 15.91
TROV's Price/Tangible Book is ranked higher than
54% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 9.40 vs. TROV: 15.91 )
TROV' s 10-Year Price/Tangible Book Range
Min: 3.8   Max: 62.6
Current: 15.91

3.8
62.6
Price/Median PS Value 2.03
TROV's Price/Median PS Value is ranked higher than
74% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. TROV: 2.03 )
TROV' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 1.66
Current: 2.03

0.32
1.66
Earnings Yield (Greenblatt) -9.50
TROV's Earnings Yield (Greenblatt) is ranked higher than
62% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. TROV: -9.50 )
TROV' s 10-Year Earnings Yield (Greenblatt) Range
Min: -18.1   Max: 0
Current: -9.5

-18.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:XE7A.Germany,
TrovaGene, Inc., was incorporated in the State of Delaware on April 26, 2002 as Used Kar Parts, Inc. On July 2, 2004, the Company acquired Xenomics, a California corporation, which was developing and commercializing TrDNA technology. As part of the acquisition, its corporate name was changed to Xenomics, Inc. (Xenomics) The Company re-domesticated its state of incorporation from Florida to Delaware and its name was changed to Trovagene, Inc. It is a development stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. Its novel tests predominantly use transrenal DNA, or Tr-DNA, and transrenal RNA, or Tr-RNA. The Company is leveraging its proprietary urine-based molecular diagnostic technology for the detection of cell-free DNA and RNA originating from diseased cell death that can be isolated from urine and detected to improve disease management. These genetic materials are also collectively referred to as cell-free nucleic acids, which result when cells in the body die and release their DNA or RNA into the bloodstream. Its fundamental urine-based molecular diagnostic platform is protected by a strong intellectual property portfolio. The Company's developed significant intellectual property around cell-free nucleic acids in urine, the extraction of cell-free nucleic acids from urine, as well as novel assay designs, particularly its proprietary non-naturally occurring primers. As of February 28, 2014, our property portfolio consists of over 130 issued patents and over 47 pending patent applications. The Company faces direct competition in the area of transrenal cell-free DNA or RNA detection and analysis is precluded by our growing patent estate. Its competitors include medical diagnostic companies, most of which have financial, technical, and marketing resources significantly greater than our resources.
» More Articles for TROV

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
TROVAGENE, INC. Financials Mar 19 2015
TROVAGENE, INC. Files SEC form 8-K, Other Events Mar 18 2015
Matthew Posard Joins Trovagene's Executive Management Team as Chief Commercial Officer Mar 18 2015
Matthew Posard Joins Trovagene's Executive Management Team as Chief Commercial Officer Mar 18 2015
TrovaGene (TROV) Enters Overbought Territory - Tale of the Tape Mar 18 2015
TrovaGene (TROV) in Focus: Stock Adds 6.1% in Session - Tale of the Tape Mar 17 2015
TrovaGene (TROV) Posts Wider Q4 Loss on Higher Expenses - Analyst Blog Mar 13 2015
Trovagene, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results Mar 12 2015
Trovagene reports 4Q loss Mar 12 2015
Trovagene reports 4Q loss Mar 12 2015
TROVAGENE, INC. Files SEC form 8-K, Results of Operations and Financial Condition Mar 12 2015
Trovagene, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results Mar 12 2015
Q4 2014 Trovagene Inc Earnings Release - 4:00 pm ET Mar 12 2015
What's in Store for TrovaGene (TROV) for Earnings Season? - Analyst Blog Mar 10 2015
TrovaGene Inc (TROV) Sees Bridger Management Buy More Shares; Other Stocks Roberto Mignone Loves Mar 03 2015
Trovagene Schedules Release of Fourth Quarter and Year End 2014 Financial Results and Investor... Feb 26 2015
Trovagene Schedules Release of Fourth Quarter and Year End 2014 Financial Results and Investor... Feb 26 2015
TROVAGENE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 11 2015
Trovagene, Inc. Announces Closing of Public Offering of Common Stock Feb 11 2015
Trovagene, Inc. Announces Closing of Public Offering of Common Stock Feb 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK